CONDITION × MEDICINE
Semaglutide is a peptide GLP-1 receptor agonist. It influences glucose regulation and appetite. The ingredient exists in different products, including injectable and oral formulations; their indications and instructions are not interchangeable.
SemaglutideType 2 diabetes / glucose control
Supports glucose-dependent insulin release.
An obesity-branded product is not an automatic substitute. Reference ↗
SemaglutideObesity / selected overweight patients
Appetite effects support medically supervised weight management.
Eligibility is product- and patient-specific. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Tirzepatide is a peptide that acts at GIP and GLP-1 receptors. Its metabolic actions connect diabetes, body weight and selected obesity-related conditions; this does not make it a universal health tonic.
TirzepatideType 2 diabetes
Acts through incretin pathways to help glucose regulation.
Match the product to the diabetes indication. Reference ↗
TirzepatideChronic weight management
Reduces appetite and food intake.
Use within a wider medical care plan. Reference ↗
Tirzepatide / ZepboundOSA with obesity: specific U.S. indication
Weight-related effects can improve this defined sleep-apnoea population.
Not a general replacement for sleep-apnoea assessment or devices. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Insulin medicines replace or supplement the action of a peptide hormone. Preparations differ in onset and duration. Human insulin and insulin analogues form a family of medicines rather than one interchangeable injection.
Insulin medicinesType 1 diabetes / hormone replacement
Provide insulin activity that is missing.
Requires individual training and monitoring. Reference ↗
Insulin medicinesType 2 diabetes / selected treatment plans
Supplement insulin when the treatment plan requires it.
Low glucose remains a major safety concern. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Teriparatide is a fragment of parathyroid hormone used as a bone-forming medicine. Its medical purpose is distinct from nutrition products marketed for general bone health.
TeriparatideOsteoporosis / selected high-fracture-risk patients
Stimulates bone formation through PTH-related signalling.
Eligibility depends on the individual bone and medical history. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Octreotide is a peptide analogue of somatostatin. It can suppress several hormone signals; that pharmacology is relevant to defined disorders, not proof of general hormone balancing.
OctreotideAcromegaly / excess growth hormone
Suppresses growth-hormone release in selected patients.
Requires specialist diagnosis and follow-up. Reference ↗
OctreotideSelected secretory tumour symptoms
Can control carcinoid-related flushing/diarrhoea and VIPoma-related diarrhoea.
Symptom control is not equivalent to cure. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Desmopressin is a synthetic peptide analogue of vasopressin. It influences water handling and can affect clotting-factor release. Different routes and preparations serve different clinical purposes.
Desmopressin injectionCentral diabetes insipidus
Provides antidiuretic activity in a defined deficiency disorder.
Do not confuse with glucose-lowering treatment. Reference ↗
Desmopressin injectionSelected haemophilia A / type I VWD
Can increase relevant clotting-factor availability.
Not suitable for all bleeding disorders or VWD types. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Peptide therapeutics include established medicines and compounds under investigation. Being a peptide, or acting in a cell or animal experiment, does not establish clinical benefit for an injected consumer product.
BPC-157Recovery claims / evidence gap
Proposed biological effects do not establish a clinical recovery benefit.
FDA identifies limited safety information and immunogenicity concerns. Reference ↗
TB-500 / thymosin beta-4 fragmentRecovery claims / evidence gap
Research terminology does not establish an approved recovery treatment.
Identity, impurities and route-specific evidence need scrutiny. Reference ↗
Injectable GHK-CuSkin/anti-ageing claims / evidence gap
Topical or mechanistic findings cannot establish injectable benefit.
Human safety data are limited for injected products. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Peptides are amino-acid chains; the boundary with small proteins is a matter of terminology. A molecular category is not a treatment indication, and an injectable presentation does not itself prove a substance is a peptide or a useful medicine.
Approved peptide medicinesDefined conditions / product-specific labels
Clinical use belongs to an exact medicine and indication.
Approval of one product does not approve an entire molecular category. Reference ↗
Compounded injectable productsQuality and evidence assessment
A preparation must be evaluated on its own evidence and quality controls.
Compounding is not the same as FDA premarket approval. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Type 2 diabetes involves insulin resistance and insufficient insulin activity. Persistent high glucose can affect blood vessels, eyes and kidneys. This background explains why glucose management and prevention of organ complications are related but distinct goals.
MetforminGlucose control
Reduces glucose production by the liver and helps insulin work.
Check kidney suitability and digestive tolerability. Reference ↗
SGLT2 inhibitorsGlucose control / selected organ protection
Increase urinary glucose removal; selected agents also have cardiovascular or kidney benefits.
Benefits and eligibility differ by agent and condition. Reference ↗
InsulinGlucose control
Provides insulin when the body needs additional insulin activity.
Requires an individualized glucose monitoring plan. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Hypertension is sustained elevation of blood pressure. It may have few symptoms while increasing cardiovascular and kidney risk. Different pathways regulate pressure, so medicines can work at different points in that system.
ACE inhibitorsLong-term blood pressure control
Reduce angiotensin signalling that narrows blood vessels.
May cause cough; kidney monitoring can be needed. Reference ↗
Losartan / ARBsLong-term blood pressure control
Block angiotensin II effects.
Suitability depends on health conditions and other medicines. Reference ↗
AmlodipineLong-term blood pressure control
Relaxes blood vessels as a calcium channel blocker.
Ankle swelling and dizziness can occur. Reference ↗
Read the guide & references →CONDITION × MEDICINE
Asthma involves variable airway narrowing and inflammation. Symptoms can fluctuate, so feeling well between attacks does not necessarily mean airway inflammation has resolved.
Inhaled corticosteroidsInflammation control
Reduce airway inflammation over time.
Technique and continued use matter; a single symptom-free day is not a stopping rule. Reference ↗
ICS–formoterol combinationsMaintenance / relief in selected plans
Combine an anti-inflammatory medicine with a bronchodilator.
Not every combination inhaler is suitable for reliever use. Reference ↗
Read the guide & references →CONDITION × MEDICINE
GERD occurs when reflux of stomach contents causes troublesome symptoms or complications. Reducing acidity can reduce injury and discomfort, but acid suppression does not remove every cause of reflux.
AntacidsShort-term symptom relief
Neutralize stomach acid already present.
Symptom relief is not confirmation of the diagnosis. Reference ↗
H2 blockersAcid suppression
Reduce stomach acid production.
Treatment intensity depends on the diagnosis. Reference ↗
Omeprazole / PPIsAcid suppression / healing
Suppress gastric acid secretion through proton pump inhibition.
Review interactions and ongoing need. Reference ↗
Read the guide & references →